How should a fasting insulin test be performed, what are the normal reference ranges, and how should abnormal results be interpreted and managed?

Fasting Insulin Testing: Performance, Reference Ranges, and Clinical Interpretation

Test Performance Requirements

Fasting insulin should be measured after an 8-hour overnight fast with no caloric intake, using a certified laboratory electrochemiluminescence immunoassay method that does not cross-react with proinsulin. 1

• Blood must be drawn in the morning after a true 8-hour fast with absolutely no caloric intake. 1
• Use venous plasma samples processed in a certified laboratory—point-of-care testing is not acceptable for diagnostic purposes. 2
• The assay must be an enzyme immunoassay or electrochemiluminescence method that specifically measures insulin without proinsulin cross-reactivity. 3, 4
• Samples should be centrifuged and separated immediately to prevent preanalytic variability. 5

Normal Reference Ranges

The most robust reference range for fasting insulin in healthy adults is 2.5–13 μU/mL (15–80 pmol/L), with no clinically significant difference between sexes. 3

• A large Brazilian database study (n=21,684) established reference intervals of 2.52–13.14 μU/mL for the overall population, with similar ranges for men (2.43–11.89 μU/mL) and women (2.54–13.30 μU/mL). 3
• An Iranian population study (n=309 healthy adults) found comparable values of 2.11–12.49 μU/mL, with a slight age-related decline in mean fasting insulin. 4
• A French population study (n=3,081 reference subjects) reported median values of 5.1–5.6 μU/mL with 95th percentiles of 11.2–12.6 μU/mL, varying slightly by age and sex. 6
• Despite statistically significant sex differences in some studies, the clinical utility of sex-specific reference ranges is not justified. 3

Interpretation of Abnormal Results

Insulin Resistance Thresholds

Fasting insulin >12 μU/mL indicates insulin resistance and warrants evaluation for metabolic syndrome, prediabetes, or type 2 diabetes risk. 7

• Insulin resistance is defined by fasting insulin ≥12 μU/mL, with calculated indices providing additional diagnostic precision. 7
• The fasting glucose-to-insulin ratio (G:I ratio) is a highly sensitive screening tool: a ratio <4.5 has 95% sensitivity and 84% specificity for detecting insulin resistance in obese women with polycystic ovary syndrome. 8
• HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) values >2.86 indicate insulin resistance, with reference range 0.39–2.86 in healthy adults. 3
• QUICKI (Quantitative Insulin Sensitivity Check Index) values <0.333 indicate insulin resistance, with normal range >0.333. 7

Clinical Algorithm for Abnormal Fasting Insulin

When fasting insulin is elevated (>12–13 μU/mL):

1. Calculate HOMA-IR: (fasting insulin in μU/mL × fasting glucose in mmol/L) / 22.5. Values >2.86 confirm insulin resistance. 3

2. Calculate fasting G:I ratio: fasting glucose (mg/dL) / fasting insulin (μU/mL). Values <6.4 suggest insulin resistance; values <4.5 indicate severe insulin resistance. 7, 8

3. Assess for diabetes or prediabetes:

   • Measure fasting plasma glucose: ≥126 mg/dL (7.0 mmol/L) indicates diabetes; 100–125 mg/dL (5.6–6.9 mmol/L) indicates prediabetes. 1, 2
   • Measure HbA1c: ≥6.5% indicates diabetes; 5.7–6.4% indicates prediabetes. 2
   • Any abnormal glucose result requires confirmation with repeat testing on a separate day unless hyperglycemic crisis or classic symptoms are present. 2, 9

4. Screen for metabolic syndrome components:

   • Measure lipid panel (triglycerides, HDL cholesterol). 9
   • Assess blood pressure and waist circumference. 4
   • Evaluate for obesity (BMI ≥25 kg/m²). 1

Management Based on Results

For confirmed insulin resistance with normal glucose (fasting insulin >12 μU/mL, HOMA-IR >2.86, but fasting glucose <100 mg/dL and HbA1c <5.7%):

• Initiate intensive lifestyle modification with structured diet and exercise programs involving multiple follow-up contacts. 9
• Address cardiovascular risk factors including hypertension, dyslipidemia, and obesity. 5, 9
• Rescreen with fasting glucose or HbA1c annually. 9
• Metformin is not indicated for isolated insulin resistance without prediabetes or diabetes. 9

For confirmed prediabetes (fasting glucose 100–125 mg/dL or HbA1c 5.7–6.4%) with elevated insulin:

• Intensive behavioral interventions (diet, exercise) are the primary strategy. 9
• Consider metformin only in high-risk individuals (BMI ≥35 kg/m², age <60 years, women with prior gestational diabetes). 1
• Annual monitoring with fasting glucose or HbA1c is mandatory. 9

For confirmed diabetes (fasting glucose ≥126 mg/dL or HbA1c ≥6.5%) with elevated insulin:

• Initiate comprehensive diabetes management including lifestyle modification and pharmacotherapy. 9
• Consider metformin as first-line agent. 5
• Screen for cardiovascular risk factors and complications. 9
• Monitor HbA1c every 3–6 months during initial treatment phase. 9

Critical Pitfalls to Avoid

• Do not diagnose insulin resistance based solely on a single elevated fasting insulin without calculating HOMA-IR or G:I ratio, as isolated insulin elevation may reflect assay variability or inadequate fasting. 3, 4
• Do not use fasting insulin alone to diagnose diabetes—glucose-based criteria (fasting glucose, HbA1c, or OGTT) are required for diabetes diagnosis. 1, 2
• Do not initiate metformin for isolated insulin resistance without confirmed prediabetes or diabetes, as this violates guideline standards. 9
• Ensure true 8-hour fasting—inadequate fasting or any caloric intake falsely elevates both glucose and insulin, leading to misclassification. 1, 5
• Do not use point-of-care glucose meters or non-certified insulin assays for diagnostic purposes. 2
• Recognize that HOMA-IR and QUICKI detect insulin resistance more reliably than glucose-to-insulin ratios alone, particularly in obese individuals where 95% have insulin resistance by calculated indices versus 77% by G:I ratio. 7